EODData

LSE, HCM: Hutchmed (China) Limited

05 Sep 2025
LAST:

235.0

CHANGE:
 20.00
OPEN:
228.0
HIGH:
240.0
ASK:
0.0
VOLUME:
147.4K
CHG(%):
9.30
PREV:
215.0
LOW:
227.9
BID:
260.0
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 25228.0240.0227.9235.0147.4K
04 Sep 25222.0231.0215.0215.030.4K
03 Sep 25221.0233.0219.0227.518.4K
02 Sep 25228.0232.6219.9227.022.8K
01 Sep 25231.0233.0218.0218.015.1K
29 Aug 25225.0232.0218.0218.211.8K
28 Aug 25217.0228.0216.0218.55.9K
27 Aug 25226.0234.8215.0226.058.9K
26 Aug 25234.0246.0222.0227.572.7K
25 Aug 25239.0244.0235.0236.010.1K

COMPANY PROFILE

Name:Hutchmed (China) Limited
About:HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Sector:Healthcare
Address:Cheung Kong Center, Hong Kong, Hong Kong
Website:https://www.hutch-med.com
ISIN:KYG4672N1198
LEI:2138006X34YDQ6OBYE79

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

P/E Ratio:5.60
Price to Book:2.13
Price to Sales:3.14
Shares:859.3M
Market Cap:201.936B

TECHNICAL INDICATORS

MA5:224.50
MA10:224.87
MA20:229.83
MA50:240.95
MA100:232.02
MA200:235.37
STO9:64.52
STO14:58.82
RSI14:50.00
WPR14:-23.08
MTM14:-6.00
ROC14:-0.02
ATR:14.67
Week High:240.00
Week Low:215.00
Month High:274.00
Month Low:202.05
Year High:336.00
Year Low:185.50
Volatility:56.83

RECENT SPLITS

Date Ratio
30 May 201910-1